- Home
- VTVT vs TCRX Comparison
VTVT vs TCRX Comparison
Compare VTVT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- TCRX
- Stock Information
- Founded
- VTVT 2015
- TCRX 2018
- Country
- VTVT United States
- TCRX United States
- Employees
- VTVT N/A
- TCRX N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- VTVT Health Care
- TCRX Health Care
- Exchange
- VTVT Nasdaq
- TCRX Nasdaq
- Market Cap
- VTVT 54.4M
- TCRX 64.1M
- IPO Year
- VTVT 2015
- TCRX 2021
- Fundamental
- Price
- VTVT $31.31
- TCRX $0.96
- Analyst Decision
- VTVT Strong Buy
- TCRX Strong Buy
- Analyst Count
- VTVT 3
- TCRX 7
- Target Price
- VTVT $37.00
- TCRX $8.50
- AVG Volume (30 Days)
- VTVT 11.5K
- TCRX 1.1M
- Earning Date
- VTVT 11-06-2025
- TCRX 11-12-2025
- Dividend Yield
- VTVT N/A
- TCRX N/A
- EPS Growth
- VTVT N/A
- TCRX N/A
- EPS
- VTVT N/A
- TCRX N/A
- Revenue
- VTVT $17,000.00
- TCRX $8,423,000.00
- Revenue This Year
- VTVT N/A
- TCRX $255.18
- Revenue Next Year
- VTVT N/A
- TCRX N/A
- P/E Ratio
- VTVT N/A
- TCRX N/A
- Revenue Growth
- VTVT N/A
- TCRX N/A
- 52 Week Low
- VTVT $13.15
- TCRX $0.91
- 52 Week High
- VTVT $33.16
- TCRX $4.94
- Technical
- Relative Strength Index (RSI)
- VTVT 68.37
- TCRX 28.17
- Support Level
- VTVT $29.40
- TCRX $0.96
- Resistance Level
- VTVT $33.16
- TCRX $1.09
- Average True Range (ATR)
- VTVT 1.88
- TCRX 0.11
- MACD
- VTVT 0.34
- TCRX -0.02
- Stochastic Oscillator
- VTVT 74.76
- TCRX 15.76
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.